FDA clears ivWatch's IV safety monitoring sensor patch

ivWatch's miniaturized SmartTouch sensor is compatible with the company's patient IV monitor, and adds options for IV site placements for neonates and children. (ivWatch)

The FDA cleared a miniaturized and disposable sensor patch designed to detect early complications from IV drug infusions—including potentially harmful leaks of medication into the surrounding tissue, such as from a misplaced needle.

Available for all ages, ivWatch’s SmartTouch device tapes over the infusion site to continuously monitor for escaping IV fluids under the skin, and is designed to alert caregivers hours before they can be detected by sight or touch.

Using an optical sensor, the patch is capable of detecting fluid infiltrations of about 2 milliliters or less. ivWatch previously developed a larger, FDA-cleared peripheral IV monitor that measures a person’s tissue fluid volume changes, and attaches to a patient’s IV pole.

Featured Whitepaper

Accelerate Clinical Operations Across Sponsors, CROs, and Partners

The most advanced life sciences organizations know that digital innovation and multi-platform integrations are essential for enabling product development. New platforms are providing the life sciences industry with an opportunity to improve the efficiency of clinical trials and reduce costs while remaining compliant and reducing risk.

The new device is compatible with the patient monitor, and adds more options for IV site placement, including for neonates and children, the company said. ivWatch plans to supply the SmartTouch sensor, which previously received a CE mark, to hospitals, infusion centers and other facilities.

The company estimates that 46 million high-risk peripheral IVs are administered in the U.S. annually, and more than 20% may fail due to fluid infiltration. 

RELATED: ivWatch snags $14M+ for IV-monitoring device

In early April, ivWatch announced a distribution partnership with The Janz Corporation to supply its monitoring products to the U.S. federal government. This includes a focus on technologies that allow clinicians to keep a close watch on patients from outside their hospital rooms, to help conserve personal protective equipment and reduce potential exposures to COVID-19.

Suggested Articles

According to a large clinical study, multifocal contact lenses were able to slow down and control the worsening of nearsightedness in children.

RapidAI has secured an FDA clearance for its artificial intelligence algorithms that quickly parse brain CT scans and spot suspected strokes.

The kits can connect 20 standard hospital beds to a central patient monitoring station and be up and running in an average of five hours.